BioSpace News Archive

Second Phase of Commercialization Advances with the Addition of Multiple Limited Release Customers

Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs), today announced financial results and operational highlights for the first quarter ended March 31, 2021.

Vir Biotechnology, Inc. reminds stockholders that it will hold its 2021 Annual General Meeting of Stockholders on Thursday, May 20, 2021, at 11:30 a.m. PT.

Allakos Inc., a biotechnology company developing lirentelimab for the treatment of eosinophil and mast cell-related diseases, reported financial results for the first quarter ended March 31, 2021 and provided a business update.

Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, will be providing an update on the clinical development of rodatristat ethyl, the company’s lead candidate for the treatment of pulmonary arterial hypertension (PAH), at the annual meeting of the American Thoracic Society

The recent study by Fact.MR on global Hospital asset management market offers a 6-year forecast between 2020 and 2026.

The recent study by Fact.MR on global endoscopy ultrasound market offers a 6-year forecast between 2020 and 2026.

Applied UV, Inc. , an infection control technology company that applies the power of narrow-range ultraviolet light for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, announced that the Company will host an investor conference call and live webcast to discuss its results on Monday, May 17, 2021 at 8:30 am EDT

According to the report, the global blood glucose monitoring systems market was valued at US$ 15.4 Bn in 2018 and is projected to expand at a CAGR of 5.5% from 2019 to 2027.

According to the report, the global breast cancer diagnostics market was valued at ~US$ 4.8 Bn in 2018 and is projected to expand at a high CAGR during the forecast period.